{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:16:38Z","timestamp":1794856598660,"version":"4.9.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02191-z","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:53:57Z","timestamp":1748228037000},"page":"985-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vimseltinib: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2191_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Silvia","year":"2023","unstructured":"Silvia S, Hans Roland D, Inga-Marie S, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112: 102491.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2191_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.56875\/2589-0646.1032","volume":"16","author":"AS Chan","year":"2023","unstructured":"Chan AS, Katiyar V, Dy P, et al. Updates on the treatment of tenosynovial giant cell tumor. Hematol Oncol Stem Cell Ther. 2023;16(4):307\u201315.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2191_CR3","unstructured":"US Food & Drug Administration. FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor [media release]. 14 Feb 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor."},{"key":"2191_CR4","unstructured":"Deciphera Pharmaceuticals. Vimseltinib development pipeline. 2025. https:\/\/www.deciphera.com\/pipeline\/vimseltinib. Accessed 17 Feb 2025."},{"key":"2191_CR5","unstructured":"Deciphera Pharmaceuticals. ROMVIMZATM (vimseltinib) capsules, for oral use: US prescribing information. 2025. https:\/\/www.deciphera.com\/sites\/default\/files\/2025-02\/DCPH-P01944%20ROMVIMZA%20Prescribing%20Information%20Feb%202025.pdf. Accessed Feb 17 2025."},{"key":"2191_CR6","unstructured":"Ono Pharmaceutical. Ono announces results of tender offer to acquire Deciphera Pharmaceuticals and completion of acquisition of Deciphera (a wholly owned subsidiary of Ono) [media release]. 11 Jun 2024. http:\/\/www.ono-pharma.com."},{"key":"2191_CR7","unstructured":"Deciphera Pharmaceuticals. Form 10-K annual report. 2024. https:\/\/www.sec.gov\/ixviewer\/ix.html?doc=\/Archives\/edgar\/data\/1654151\/000165415124000004\/dcph-20231231.htm. Accessed 10 Mar 2025."},{"key":"2191_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bmcl.2022.128928","volume":"74","author":"TM Caldwell","year":"2022","unstructured":"Caldwell TM, Ahn YM, Bulfer SL, et al. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of tenosynovial giant cell tumor (TGCT). Bioorg Med Chem Lett. 2022;74:1\u20137.","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"2191_CR9","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","volume":"20","author":"BD Smith","year":"2021","unstructured":"Smith BD, Kaufman MD, Wise SC, et al. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Mol Cancer Ther. 2021;20(11):2098\u2013109.","journal-title":"Mol Cancer Ther"},{"issue":"10445","key":"2191_CR10","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445):2709\u201319.","journal-title":"Lancet"},{"key":"2191_CR11","doi-asserted-by":"crossref","unstructured":"Gelderblom H, Bhadri VA, Stacchiotti S, et al. Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): one-year follow-up from the MOTION phase III trial [abstract no. LBA78 plus presentation]. In: Ann Oncol. 2024.","DOI":"10.1016\/j.annonc.2024.08.2321"},{"issue":"18","key":"2191_CR12","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","volume":"30","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Razak AA, Taylor MH, et al. CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase I study of vimseltinib. Clin Cancer Res. 2024;30(18):3996\u20134004.","journal-title":"Clin Cancer Res"},{"key":"2191_CR13","unstructured":"Deciphera Pharmaceuticals. European Medicines Agency accepts Deciphera's marketing authorization application for vimseltinib for treatment of patients with tenosynovial giant cell tumor (TGCT) [media release]. 19 Jul 2024. http:\/\/www.deciphera.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02191-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:18Z","timestamp":1750694118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02191-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02191-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}